Keiran S. M. Smalley
The Wistar Institute
Philadelphia
PA 19104
USA
Name/email consistency: high
- An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Smalley, K.S., Contractor, R., Haass, N.K., Kulp, A.N., Atilla-Gokcumen, G.E., Williams, D.S., Bregman, H., Flaherty, K.T., Soengas, M.S., Meggers, E., Herlyn, M. Cancer Res. (2007)
- Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Smalley, K.S., Contractor, R., Haass, N.K., Lee, J.T., Nathanson, K.L., Medina, C.A., Flaherty, K.T., Herlyn, M. Br. J. Cancer (2007)
- Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Smalley, K.S., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T., Herlyn, M. Mol. Cancer Ther. (2006)
- Life isn't flat: taking cancer biology to the next dimension. Smalley, K.S., Lioni, M., Herlyn, M. In Vitro Cell. Dev. Biol. Anim. (2006)
- Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Smalley, K.S., Lioni, M., Herlyn, M. Expert. Rev. Anticancer. Ther (2005)